Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are Semaglutide USA supplier anticipating strong results driven by the continued success of Lilly's blockbuster treatments, particularly its insulin port